内蒙古民族大学学报（自然科学版）
內矇古民族大學學報（自然科學版）
내몽고민족대학학보（자연과학판）
JOURNAL OF INNER MONGOLIA UNIVERSITY FOR NATIONALITIES(NATURAL SCIENCES)
2013年
6期
710-711
,共2页
培美曲塞二钠%铂类%晚期非小细胞肺癌
培美麯塞二鈉%鉑類%晚期非小細胞肺癌
배미곡새이납%박류%만기비소세포폐암
Pemetrexed disodium%Platinum-based%Advanced non-small cell lung cancer
目的：探讨培美曲塞二钠联合铂类方案二线治疗晚期非小细胞肺癌（NSCLC）的疗效和不良反应.方法：16例既往化疗失败的晚期NSCLC患者接受培美曲塞二钠联合铂类方案化疗,其中培美曲塞二钠500 mg/m2加入0.9%氯化钠注射液100 ml静脉滴注超过10 min，第1天；顺铂75 mg/m2或卡铂剂量AUC=5第2天，静脉滴注.每21 d重复,2周期评价疗效.结果：16例患者中,无CR病例，PR 2例,SD 8例,PD 6例,RR12.6%,DCR为62.5%.主要的不良反应是骨髓抑制、消化道反应和口腔粘膜炎，多为I～Ⅱ度，经对症治疗后可以缓解，不影响继续用药.结论：培美曲塞二钠联合铂类方案二线治疗晚期NSCLC安全有效，耐受性好.
目的：探討培美麯塞二鈉聯閤鉑類方案二線治療晚期非小細胞肺癌（NSCLC）的療效和不良反應.方法：16例既往化療失敗的晚期NSCLC患者接受培美麯塞二鈉聯閤鉑類方案化療,其中培美麯塞二鈉500 mg/m2加入0.9%氯化鈉註射液100 ml靜脈滴註超過10 min，第1天；順鉑75 mg/m2或卡鉑劑量AUC=5第2天，靜脈滴註.每21 d重複,2週期評價療效.結果：16例患者中,無CR病例，PR 2例,SD 8例,PD 6例,RR12.6%,DCR為62.5%.主要的不良反應是骨髓抑製、消化道反應和口腔粘膜炎，多為I～Ⅱ度，經對癥治療後可以緩解，不影響繼續用藥.結論：培美麯塞二鈉聯閤鉑類方案二線治療晚期NSCLC安全有效，耐受性好.
목적：탐토배미곡새이납연합박류방안이선치료만기비소세포폐암（NSCLC）적료효화불량반응.방법：16례기왕화료실패적만기NSCLC환자접수배미곡새이납연합박류방안화료,기중배미곡새이납500 mg/m2가입0.9%록화납주사액100 ml정맥적주초과10 min，제1천；순박75 mg/m2혹잡박제량AUC=5제2천，정맥적주.매21 d중복,2주기평개료효.결과：16례환자중,무CR병례，PR 2례,SD 8례,PD 6례,RR12.6%,DCR위62.5%.주요적불량반응시골수억제、소화도반응화구강점막염，다위I～Ⅱ도，경대증치료후가이완해，불영향계속용약.결론：배미곡새이납연합박류방안이선치료만기NSCLC안전유효，내수성호.
Objective:To investigate the efficacy and adverse reactions of pemetrexed disodium combined with plati-num second-line in the treatment of advanced non-small-cell lung cancer (NSCLC). Methods:16 cases of advanced NSCLC patients whose past chemotherapy were failure, received pemetrexed disodium combined with platinum-based chemotherapy. On the first day, the pemetrexed disodium 500 mg/m2 was added into 100 ml 0.9%sodium chloride in-jection and intravenously infused over 10 min;on the second day, the cisplatin 75 mg/m2 or carboplatin dosage AUC=5 intravenously infused. Repeated every 21 days, and the efficacy was evaluated after 2 treatment cycles. Results:In 16 patients, CR 0 case, PR 2 cases, SD 8 cases, PD 6 cases, RR accounted for 12.6%and DCR 62.5%. The main adverse reactions were bone marrow suppression, gastrointestinal reactions and oral mucositis, most of them wereⅠtoⅡdegree, could alleviate after symptomatic treatment, and did not affect the continued medication. Conclusion:Pemetrexed di-sodium combined with platinum second-line is safe and effective to treat advanced NSCLC, and has a good tolerance.
